Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess...

35
Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd , 2005

Transcript of Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess...

Page 1: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Therapeutic Cardiac Ultrasound

Graham Gardner, M.D.

Division of Cardiology

Beth Israel Deaconess Medical Center

Harvard Medical School

February 2nd, 2005

Page 2: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Introduction

• Novel Mechanisms for Drug Delivery

• Drug Delivery using Ultrasound

• Advantages and Disadvantages of Cardiac Ultrasound

• Specific Applications – Drug Delivery

– Gene Delivery

• Future Directions

Page 3: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Novel Mechanisms for Drug Delivery

Challenges

• Systemic toxicities

• Degradation (proteins)

• Invasive delivery systems

• Metabolism / time to onset

Solutions

• Local / targeted delivery

• Controlled release / stability

• Non-invasive

• Immediate onset

Page 4: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Novel Mechanisms for Drug Delivery

Innovations

– Nanotechnology

– Controlled-release devices and preparations

– Marriage of pharmaceutical compounds with medical devices

– Ultrasound-enabling

Page 5: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Cardiac Ultrasound Principles

• Creation of microspheres

• Incorporation of drugs (and possibly ligands) within the microspheres

• Distribution of drug-containing microspheres through the vascular system

• Delivery of the drugs to target organs via ultrasound

Page 6: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Microsphere Constituents

• Gas– Air: dissolution in blood is < 1 sec– Perflurocarbons

• Low propensity to diffuse remains in the bubble• Low concentration of saturation in blood prolonged

survival

• Shell– Albumin: flexible and binds to injured endothelium– Acrylates: inflexible and require ultrasound destruction– Polymers: custom-designed

Page 7: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Microsphere Formulation

Microsphere Constituents

• Gas– Room air– Perfluorocarbons

• Shell / surface– Fatty acids– Phospholipids– Albumin– Antibodies– Polymers

Microphere Properties

• Cross-sectional area• Persistence / fragility• Resonance• Attenuation• Adhesion

Page 8: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Microsphere Formulation

Drug and Ligand Formulation

• Microspheres can be formulated with multiple different drugs and act as carrier molecules

• Specific ligands can also be attached to help direct the microspheres to a specific organ or disease process

www.hd.org

Page 9: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Injection of Microspheres

www.ocularvision.comwww.ergonext.com

The microspheres can be introduced into the vascular system through regular intravenous access

Page 10: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Application of Ultrasound

• Ultrasound applied over the skin surface can be used to burst the microbubbles over the target area for drug delivery

• Microspheres themselves act as nuclei for cavitation

Page 11: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

EKG-Gating for Coronary Delivery

www.emedhome.com

Page 12: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Destruction of the Microspheres

• Gradual diffusion of gas at low acoustical power

• Formation of shell defect diffusion of gas

• Immediate explosion of the microsphere shell at high acoustical power

• Dispersion of the microspheres into small bubbles

Tsutsui JM, etal. Cardiovascular Ultrasound, 2004.

Page 13: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Additional Effects of Ultrasound

• Creation of extravasation points in skeletal muscle capillaries (micro-fractures)– Microvessels with diameter < 7 um

– Dependent upon ultrasound pulse interval (optimal approx 5 sec)

• Formation of pores in cellular membranes– Best with lower Hz / higher wavelength

• Physical disruption of clot

Tsutsui JM, etal. Cardiovascular Ultrasound, 2004.

Page 14: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Advantages of Ultrasound

• Local or targeted delivery

• Minimize systemic circulation and drug levels

• Delivery of “difficult” compounds– Proteins

– Systemically toxic compounds

• Non-invasive

• Ultrasound facilitation of drug delivery– Microvessel fractures

– Clot dissolution

– Disruption of lipid cellular membranes

Page 15: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Disadvantages of Ultrasound

• “Packaging” requirements– Limitation of total amount

• Cost

• Safety considerations– PVCs

– Disruption of the microvasculature

– Allergy to microsphere preparations or constituents

Page 16: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Specific Applications

• Drug Delivery– Thrombolysis

– Myocarditis

– Angiogenesis

– Restenosis

• Gene Delivery– Cellular transfection

Page 17: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Specific Applications

• Drug Delivery– Thrombolysis

– Myocarditis

– Angiogenesis

– Restenosis

• Gene Delivery– Cellular transfection

Page 18: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Thrombolysis Study: Siegel et al.

• Methods– Bilateral Thrombi in the femoral

and coronary arteries of rabbits induced via electrical current

– Thrombosis confirmed via angiography

– Randomization to 2 of several arms• Ultrasound alone (20-37 kHz)• Thrombolytic alone• Microbubbles alone• Thrombolytic and ultrasound• Microbubbles and ultrasound

Siegel RJ, et al. Echocardiography, 2001.

Page 19: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Thrombolysis Study: Siegel et al.

Siegel RJ, et al. Echocardiography, 2001.

Page 20: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Thrombolysis Study: Siegel et al.

• Significantly improved recanalization of femoral arteries with the application of ultrasound to streptokinase or microbubbles compared with streptokinase or microbubbles alone

Siegel RJ, et al. Echocardiography, 2001.

Page 21: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Thrombolysis Study: Siegel et al.

• Results (coronary)– Significantly improved

patency rates at 30 and 90 minutes when TPA combined with ultrasound

– TIMI 2-3 flow seen in 25% of tPA alone vs 92% of ultrasound-tPA combination

– No assessment of LV function

Siegel RJ, et al. Echocardiography, 2001.

Page 22: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Thrombolysis Study: Siegel et al.

Siegel RJ, et al. Echocardiography, 2001.

Page 23: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Specific Applications

• Drug Delivery– Thrombolysis

– Myocarditis

– Angiogenesis

– Restenosis

• Gene Delivery– Cellular transfection

Page 24: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Restenosis

• Synthetic antisense oligonucleotides (c-myc protooncogene) can bind to mRNA and inhibit the synthesis of the protooncogene

• By inhibiting the c-myc protooncogene, these antisense oligonucleotides could inhibit restenosis after vascular injury

Page 25: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Restenosis Study: Porter et al

• Methods– 21 pigs– Injury to the R carotid artery via oversized balloon inflation– Vessel patency confirmed via angiography– Randomized to three arms

• Synthetic oligodeoxynucleaotide to c-myc• Synthetic oligodeoxynucleaotide to c-myc bound with albumin-coated

microbubbles• Control

– Injected at Time 0 and again at 3 days– Ultrasound applied at 20 kHz– Harvesting performed at 30 days

Porter TR, et al. Ultrasound in Med & Biol, 2001.

Page 26: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Restenosis Study: Porter et al

• Results– Lumen area was significantly

larger at the injury site in pigs that received ODN-myc combined with microbubbles (reduction of 8 +/- 2% vs 19% and 28% in the control and antisense alone groups)

Porter TR, et al. Ultrasound in Med & Biol, 2001.

Page 27: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Specific Applications

• Drug Delivery– Thrombolysis

– Myocarditis

– Angiogenesis

– Restenosis

• Gene Delivery– Cellular transfection

Page 28: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Transfection Study: Bekeredjian et al.

• Methods– Albumin microbubbles with a plasmid encoding luciferase

– Injected into internal jugular vein

– Sonos 5500 with S3 transducer applied to chest wall (1.3 MHz)

– Variable transfection and harvesting timepoints

– Hearts dissected

Page 29: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Transfection Study: Bekeredjian et al.

• Results– Highest transfection rate

seen after 4 days but still detectable at 28 days

– Transfection almost exclusively confined to the heart

– Little transfection seen when ultrasound and microbubble injections separated temporally

Page 30: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Transfection Study: Shohet et al.

• Methods– Perfluoropropane-filled albumin microbubbles

– Attached to adenovirus containing cDNA for E coli β-galactosidase gene

– Rats divided into 6 groups• Echocardiographic destruction of microbubbles without gene

• Echocardiographic destruction of microbubbles with gene

• Microbubbles with gene only

• Gene alone

• Echocardiography with gene alone

• Echocardiographic destriction of microbubbles without gene followed by the infusion of gene alone

Page 31: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Transfection Study: Shohet et al.

• Results– Livers of any animal

receiving some adenovirus showed some activity

– All hearts receiving microbubbles, gene, and ultrasound showed uptake

– No skeletal muscles in this experimental group showed uptake

– No uptake was seen in the hearts of any other animals

Page 32: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Transfection Study: Shohet et al.

• Results– β-galactosidase activity was

10-fold higher in the experimental group that received gene-encoated microbubbles and ultrasound simultaneously

– β-galactosidase activity was 2-fold higher in the group that received microbubble and ultrasound destruction first, followed by gene infusion.

Page 33: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Future Directions

• Application to other disease processes– Oncology

• Delivery of chemotherapy

• Delivery of anti-angiogenesis factors

– Musculoskeletal (arthritis)

– GI

– Endocrine (insulin delivery for diabetes)

– Transdermal drug delivery

Page 34: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

Future Directions

• Cardiology Applications– Angiogenesis

• Delivery of VEGF

– Enhanced imaging• Ischemic myocardium

– Arrhythmia management• Combination of monitoring and therapy

Page 35: Therapeutic Cardiac Ultrasound Graham Gardner, M.D. Division of Cardiology Beth Israel Deaconess Medical Center Harvard Medical School February 2 nd, 2005.

? Management of Acute Myocardial Infarctions

www.mayoclinic.org